Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis

Conclusions: Our work comprehensively summarized and analyzed current available RCT-based evidence of the second-line treatments for trastuzumab-treated, HER2-positive, advanced breast cancer. These results provide clinicians and oncologists meaningful references for clinical drug administration and the development of novel effective therapies.

Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Fei Chen, Naifei Chen, Zheng Lv, Lingyu Li, Jiuwei Cui Tags: Research Paper Source Type: research